🌟 Product Overview
Ozagrel Sodium (CAS: 130952-46-4) is a selective thromboxane A2 synthase inhibitor widely recognized for its antiplatelet activity, effectively preventing thrombus formation in cardiovascular conditions such as acute ischemic stroke and peripheral arterial occlusion. With a molecular formula of C₁₃H₁₁N₂NaO₂ and molecular weight of 250.23, this compound reduces platelet aggregation by over 80% in clinical studies. It is a critical component in pharmaceutical manufacturing, clinical therapy, and cardiovascular research, supporting advanced treatments for thrombotic disorders.
✅ Key Advantages
💊 High Efficacy: Clinically proven to reduce platelet aggregation by >80%.
🔬 Premium Quality: ≥98% purity (HPLC/GC-certified), compliant with USP/EP standards.
📦 Stability: Stable under ambient storage with long-term shelf life.
🧪 Structural Verification: Confirmed by NMR, MS, and chromatographic analysis.
📌 Applications
• Pharmaceuticals: Key intermediate in antiplatelet drug formulations.
• Clinical Use: Approved for ischemic stroke and thrombosis management.
• Research: Investigated for neuroprotective and anti-inflammatory properties.
🔍 Quality Certifications
• Complies with USP/EP guidelines for impurities, heavy metals, and residual solvents.
• Batch-specific COA includes purity (≥98%), pH (8.0–9.5), and moisture content (≤0.5%).
• Rigorous testing via HPLC (>95% purity), NMR, and mass spectrometry.
📈 Market Trends
The global cardiovascular drug market is projected to grow at 5.2% CAGR (2025–2030), driven by rising thrombosis and stroke prevalence. Ozagrel Sodium holds a significant share in antiplatelet APIs, with expanding demand in Asia-Pacific and Europe.
Google Keywords: Ozagrel Sodium CAS 130952-46-4, cardiovascular API, antiplatelet agent, USP/EP certified, pharmaceutical supplier.
China
